---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-009981"
form_type: "8-K"
ticker: "HIND"
cik: "0001427570"
company_name: "Vyome Holdings, Inc"
filed_at: "2023-05-16T23:59:59+00:00"
generated_at: "2026-06-14T23:29:48.815244+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ReShape Lifesciences Q1 2023 revenue down 6.3% to $2.3M; operating expenses cut 42.9% YoY

## Summary
- Revenue $2.3M (down 6.3% YoY); gross margin improved to 53.5% from 49.9%.
- Sales & marketing expenses fell 53.5% to $2.2M; R&D down 39.2% to $0.5M.
- Cash $9.1M at March 31, 2023; no debt; expects runway into 2024.
- Raised $12.7M in 2023 via February public offering ($10.2M) and April direct offering ($2.5M).
- Lap-Band 2.0 PMA supplement submission to FDA expected in coming weeks; feedback by year-end.

## SEC filing metadata
- accession: 0001558370-23-009981
- form_type: 8-K
- ticker: HIND
- cik: 0001427570
- company_name: Vyome Holdings, Inc
- filed_at: 2023-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427570/000155837023009981/0001558370-23-009981-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427570/000155837023009981/rsls-20230515x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-009981
- JSON: https://secwatch.observer/filing/0001558370-23-009981.json
- Plain text: https://secwatch.observer/filing/0001558370-23-009981.txt

## Key facts
- Earnings Releases
  Vyome Holdings, Inc reported for the three months ended March 31, 2023 results: revenue $2.3 million.
  - Period: for the three months ended March 31, 2023
  - Revenue: $2.3 million
  - Result: reported results
  source text: impact revenue for the remainder of 2023 and move ReShape closer to cash flow breakeven.” ​ First Quarter Ended March 31, 2023, Financial and Operating Results ​ Revenue totaled $2.3 million for the three months ended March 31, 2023, which represents a contraction of 6.3%, or $0.2 million compared to the same period in 2022. The primary reason for the decrease is a
  evidence_url: https://www.sec.gov/Archives/edgar/data/1427570/000155837023009981/0001558370-23-009981-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.